Investors and Media

Press Release Details

Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations

June 1, 2022

-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation –

-- Global nomination deadline of August 1, 2022 --

NEW HAVEN, Conn., June 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced a global call for entries for their inaugural Early Career Research Award. This award will recognize the efforts of up-and-coming researchers bringing innovation, new approaches and creative thinking to advance the field of targeted protein degradation; acknowledging their dedication and commitment to this therapeutic approach toward otherwise intractable disease targets. The winner will receive a $25,000 monetary award and will be recognized and formally presented with this award at the 5th Annual Targeted Protein Degradation Summit, October 25-28, 2022, in Boston. Applications will be accepted today through August 1, 2022, at midnight Eastern Time. Full eligibility criteria and details on the application process can be found on

“Arvinas is proud to be a leader in targeted protein degradation, and we are very pleased to honor 20 years of targeted protein degradation by fostering innovation in this field through the recognition of the efforts of an up-and-coming researcher within this space,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas. “Our hope is that the brightest minds driving the growth and development of the targeted protein degradation biopharmaceutical community will be nominated for the Arvinas Early Career Researcher Award for a chance to earn the recognition they deserve.”

Researchers in academia, at either the graduate or postdoctoral level at the time of studies conducted and/or published, will be eligible for this award. Applicants must have demonstrated professional and scientific leadership in protein degradation and exhibited scientific curiosity and an established pattern of creative thinking and must not have a direct role in patient diagnosis and/or treatment. Only applicants who meet the full eligibility criteria will be considered.

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic benefits of ARV-471, bavdegalutamide, ARV-766 and our other product candidates, and the future development and potential marketing approval and commercialization of ARV-471, bavdegalutamide, ARV-766 and our other product candidates. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully conduct and complete clinical development, including whether we initiate and receive results from our clinical trials on our expected timelines or at all, obtain marketing approval for and commercialize ARV-471, bavdegalutamide, ARV-766 and our other product candidates on our current timelines or at all and other important factors discussed in the “Risk Factors” sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.

Arvinas Contacts

Jeff Boyle

Kirsten Owens